Physiologically based pharmacokinetic modeling of tea catechin mixture in rats and humans

Abstract

Although green tea ( Camellia sinensis) ( GT) contains a large number of polyphenolic compounds with anti‐oxidative and anti‐proliferative activities, little is known of the pharmacokinetics and tissue dose of tea catechins ( TCs) as a chemical mixture in humans. The objectives of this study were to develop and validate a physiologically based pharmacokinetic ( PBPK) model of tea catechin mixture ( TCM) in rats and humans, and to predict an integrated or total concentration of TCM in the plasma of humans after consuming GT or Polyphenon E ( PE). To this end, a PBPK model of epigallocatechin gallate ( EGCg) consisting of 13 first‐order, blood flow‐limited tissue compartments was first developed in rats. The rat model was scaled up to humans by replacing its physiological parameters, pharmacokinetic parameters and tissue/blood partition coefficients ( PCs) with human‐specific values. Both rat and human EGCg models were then extrapolated to other TCs by substituting its physicochemical parameters, pharmacokinetic parameters, and PCs with catechin‐specific values. Finally, a PBPK model of TCM was constructed by linking three rat (or human) tea catechin models together without including a description for pharmacokinetic interaction between the TCs. The mixture PBPK model accurately predicted the pharmacokinetic behaviors of three individual TCs in the plasma of rats and humans after GT or PE consumption. Model‐predicted total TCM concentration in the plasma was linearly related to the dose consumed by humans. The mixture PBPK model is able to translate an external dose of TCM into internal target tissue doses for future safety assessment and dose‐response analysis studies in humans. The modeling framework as described in this paper is also applicable to the bioactive chemical in other plant‐based health products.